KUALA LUMPUR, Aug 7 (Bernama) -- Neuralstem Inc -- a biopharmaceutical company focused on the development of nervous system therapies -- has appointed Jim Scully as interim chief executive officer (CEO).
Scully succeeds Rich Daly who served as president and CEO of the company since February 2016, a statement said. “Jim is an experienced pharmaceutical executive with a deep understanding of commercial, clinical development and manufacturing operations and has worked with our team to advance our company’s efforts in China and rest-of-world,” said Chair of the Nominating Committee of Neuralstem, Cristina Csimma. She added that Scully’s contribution in business development as strategic advisor for Neuralstem has been extremely valuable and the appointment will ensure continued momentum over the near-term as the company search efforts continue. Previously, Scully assumed roles of increasing responsibility across multiple functional areas, leading efforts in financial planning, global business development and business analytics during his time with Takeda Pharmaceuticals. The board also appointed William Oldaker as company’s chairman. Oldaker served as a director of Neuralstem since April 2007. -- BERNAMA
0 Comments
Leave a Reply. |
Archives
April 2023
|